Crystal forms of saxagliptin and processes for preparing same
First Claim
1. A crystalline compound of form H2-1 (1HCl), H2-1 (2HCl), H0.75-3, H1.67-1, P-5, or mixtures thereof,wherein the crystalline compound of form H2-1 (1HCl) has structure
3 Assignments
0 Petitions
Accused Products
Abstract
Physical crystal structures of a compound of the formula I:
are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
-
Citations
46 Claims
-
1. A crystalline compound of form H2-1 (1HCl), H2-1 (2HCl), H0.75-3, H1.67-1, P-5, or mixtures thereof,
wherein the crystalline compound of form H2-1 (1HCl) has structure
-
11. A pharmaceutical composition comprising a therapeutically effective amount of crystalline compound of form H2-1 (1HCl), H2-1 (2HCl), H0.75-3, H1.67-1, P-5, or mixtures thereof, and a pharmaceutically acceptable carrier, wherein:
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418Å
) of 6.8±
0.1, 11.1±
0.1, 13.7±
0.1, 14.6±
0.1, 15.2±
0.1, 16.4±
0.1, 17.0±
0.1, 20.2±
0.1, and 21.1±
0.1;
the crystalline compound of form H2-1 (2HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 7.2±
0.1, 8.6±
0.1, 11.6±
0.1, 14.3±
0.1, 15.7±
0.1, 19.5±
0.1, and 22.5±
0.1;
the crystalline compound of form H0.75-3 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.0±
0.1, 7.0±
0.1, 8.1±
0.1, 11.4±
0.1, 13.4±
0.1, 14.0±
0.1, 14.5±
0.1, 18.6±
0.1, 19.4±
0.1, and 20.0±
0.1;
the crystalline compound of form H1.67-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.4±
0.1, 7.0±
0.1, 13.8±
0.1, 14.2±
0.1, 14.6±
0.1, 16.1±
0.1, 16.6±
0.1, 18.6±
0.1, 19.0±
0.1, and 20.3±
0.1; and
the crystalline compound of form P-5 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.2±
0.1, 10.7±
0.1, 14.5±
0.1, 15.0±
0.1, 15.6±
0.1, 16.2±
0.1, 18.1±
0.1, 18.7±
0.1, and 21.1±
0.1.
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
-
12. A pharmaceutical combination comprising a therapeutically effective amount of crystalline compound of form H2-1 (1HCl), H2-1 (2HCl), H0.75-3, H1.67-1, or P-5, and at least one or more antidiabetic agent(s) other than a DPP4 inhibitor for treating diabetes, wherein:
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.8±
0.1, 11.1±
0.1, 13.7±
0.1, 14.6±
0.1, 15.2±
0.1, 16.4±
0.1, 17.0±
0.1, 20.2±
0.1, and 21.1±
0.1;
the crystalline compound of form H2-1 (2HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 7.2±
0.1, 8.6±
0.1, 11.6±
0.1, 14.3±
0.1, 15.7±
0.1, 19.5±
0.1, and 22.5±
0.1;
the crystalline compound of form H0.75-3 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.0±
0.1, 7.0±
0.1, 8.1±
0.1, 11.4±
0.1, 13.4±
0.1, 14.0±
0.1, 14.5±
0.1, 18.6±
0.1, 19.4±
0.1, and 20.0±
0.1;
the crystalline compound of form H1.67-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.4±
0.1, 7.0±
0.1, 13.8±
0.1, 14.2±
0.1, 14.6±
0.1, 16.1±
0.1, 16.6±
0.1, 18.6±
0.1, 19.0±
0.1, and 20.3±
0.1; and
the crystalline compound of form P-5 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.2±
0.1, 10.7±
0.1, 14.5±
0.1, 15.0±
0.1, 15.6±
0.1, 16.2±
0.1, 18.1±
0.1, 18.7±
0.1, and 21.1±
0.1. - View Dependent Claims (13, 14, 15, 16, 17)
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
-
18. A pharmaceutical combination comprising a therapeutically effective amount of crystalline compound of form H2-1 (1HCl), H2-1 (2HCl), H0.75-3, H1.67-1, or P-5, and an anti-obesity agent, wherein:
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.8±
0.1, 11.1±
0.1, 13.7±
0.1, 14.6±
0.1, 15.2±
0.1, 16.4±
0.1, 17.0±
0.1, 20.2±
0.1, and 21.1±
0.1;
the crystalline compound of form H2-1 (2HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 7.2±
0.1, 8.6±
0.1, 11.6±
0.1, 14.3±
0.1, 15.7±
0.1, 19.5±
0.1, and 22.5±
0.1;
the crystalline compound of form H0.75-3 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.0±
0.1, 7.0±
0.1, 8.1±
0.1, 11.4±
0.1, 13.4±
0.1, 14.0±
0.1, 14.5±
0.1, 18.6±
0.1, 19.4±
0.1, and 20.0±
0.1;
the crystalline compound of form H1.67-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.4±
0.1, 7.0±
0.1, 13.8±
0.1, 14.2±
0.1, 14.6±
0.1, 16.1±
0.1, 16.6±
0.1, 18.6±
0.1, 19.0±
0.1, and 20.3±
0.1; and
the crystalline compound of form P-5 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.2±
0.1, 10.7±
0.1, 14.5±
0.1, 15.0±
0.1, 15.6±
0.1, 16.2±
0.1, 18.1±
0.1, 18.7±
0.1, and 21.1±
0.1. - View Dependent Claims (19)
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
-
20. A pharmaceutical combination comprising a therapeutically effective amount of crystalline compound of form H2-1 (1HCl), H2-1 (2HCl), H0.75-3, H1.67-1, or P-5, and a lipid-modulating agent, wherein:
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.8±
0.1, 11.1±
0.1, 13.7±
0.1, 14.6±
0.1, 15.2±
0.1, 16.4±
0.1, 17.0±
0.1, 20.2±
0.1, and 21.1±
0.1;
the crystalline compound of form H2-1 (2HCl) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 7.2±
0.1, 8.6±
0.1, 11.6±
0.1, 14.3±
0.1, 15.7+0.1, 19.5±
0.1, and 22.5±
0.1;
the crystalline compound of form H0.75-3 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.0±
0.1, 7.0±
0.1, 8.1±
0.1, 11.4±
0.1, 13.4±
0.1, 14.0±
0.1, 14.5±
0.1, 18.6±
0.1, 19.4±
0.1, and 20.0±
0.1;
the crystalline compound of form H1.67-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.4±
0.1, 7.0±
0.1, 13.8±
0.1, 14.2±
0.1, 14.6±
0.1, 16.1±
0.1, 16.6±
0.1, 18.6±
0.1, 19.0±
0.1, and 20.3±
0.1; and
the crystalline compound of form P-5 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.2±
0.1, 10.7±
0.1, 14.5±
0.1, 15.0±
0.1, 15.6±
0.1, 16.2±
0.1, 18.1±
0.1, 18.7±
0.1, and 21.1±
0.1. - View Dependent Claims (21)
- the crystalline compound of form H2-1 (1HCl) has powder x-ray diffraction peaks at 2θ
-
22. A process for preparing crystalline compound of form H2-1 (1HCl) having powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 6.8±
0.1, 11.1±
0.1, 13.7±
0.1, 14.6±
0.1, 15.2±
0.1, 16.4±
0.1, 17.0±
0.1, 20.2±
0.1, and 21.1±
0.1, comprising;(a) dissolving saxagliptin trifluoroacetic acid salt in water; (b) adjusting the pH of the aqueous solution of step (a) to a pH within the range from 9 to 9.8 with a strong base; (c) treating the mixture from step (b) with an organic solvent to extract the aqueous layer from the organic layer; (d) adding a solution of hydrochloric acid to the organic solution of step (c); (e) evaporating the organic solution of step (d) to dryness; (f) dissolving the resulting solids from step (e) in an alcohol solvent; (g) heating the solution from step (f) to a temperature within the range from 35 to 60°
C.;(h) adding t-butylmethyl ether (MTBE) to the heated solution from step (g) to form a slurry; (i) cooling the slurry from step (h); (j) filtering the slurry from step (i); and (l) drying the resulting wet cake from step (j) to obtain the crystalline compound of form H2-1 (1HCl).
- values (CuKα
-
23. A process for preparing crystalline compound of form H2-1 (2HCl) having powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 7.2±
0.1, 8.6±
0.1, 11.6±
0.1, 14.3±
0.1, 15.7±
0.1, 19.5±
0.1, and 22.5±
0.1, comprising;(a) dissolving crystalline compound of form H-1 (1H2O) in HCl, dioxane and ethanol; and (b) upon standing at room temperature, isolating the crystalline compound of form H2-1 (2HCl).
- values (CuKα
-
24. A process for preparing crystalline compound of form H1.67-1 having powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 5.4±
0.1, 7.0±
0.1, 13.8±
0.1, 14.2±
0.1, 14.6±
0.1, 16.1±
0.1, 16.6±
0.1, 18.6±
0.1, 19.0±
0.1, and 20.3±
0.1, comprising;(a) dissolving Boc protected compound
- values (CuKα
-
25. A process for preparing crystalline compound of form H0.75-3 having x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 5.0±
0.1, 7.0±
0.1, 8.1±
0.1, 11.4±
0.1, 13.4±
0.1, 14.0±
0.1, 14.5±
0.1, 18.6±
0.1, 19.4±
0.1, and 20.0±
0.1, comprising;(a) heating crystalline compound of form H2-1 (1HCl) at a temperature from 25 to 55°
C. for 1 to 2 hours; and(b) isolating the crystalline compound of form H0.75-3 from step (a).
- values (CuKα
-
26. A process for preparing crystalline compound of form P-5 having x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 6.2±
0.1, 10.7±
0.1, 14.5±
0.1, 15.0±
0.1, 15.6±
0.1, 16.2±
0.1, 18.1±
0.1, 18.7±
0.1, and 21.1±
0.1, comprising;(a) dissolving crystalline compound of form H2-1 (1HCl) in ethanol with heating at 35 to 50°
C.;(b) allowing the mixture of step (a) to cool to 20 to 30°
C.; and(c) isolating the crystalline compound of form P-5 from the mixture of step (b).
- values (CuKα
-
27. A crystalline compound of form N-3, H-1 (1H2O), H-1 (1PhCO2H/1H2O), and N-1,
wherein the crystalline compound of form N-3 has structure
-
36. A pharmaceutical composition comprising a therapeutically effective amount of crystalline compound of form N-3, H-1 (1H2O), H-1 (1PhCO2H/1H2O), or N-1, and a pharmaceutically acceptable carrier, wherein the crystalline compound of form N-3 has powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 5.2±
0.1, 7.9±
0.1, 10.8±
0.1, 11.5±
0.1, 13.0±
0.1, 14.6±
0.1, 15.6±
0.1, 15.9±
0.1, and 16.5±
0.1;
wherein the crystalline compound of form H-1 (1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 12.4±
0.1, 13.3±
0.1, 13.6±
0.1, 14.7±
0.1, 16.2±
0.1, 18.2±
0.1, 19.9±
0.1, 20.9±
0.1, 21.9±
0.1, and 22.4±
0.1;
wherein the crystalline compound of form H-1 (1PhCO2H/1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.6±
0.1, 8.3±
0.1, 15.3±
0.1, 16.1±
0.1, 16.9±
0.1, 17.5±
0.1, 17.8±
0.1, 18.6±
0.1, and 21.3±
0.1; and
wherein the crystalline compound of form N-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.5±
0.1, 7.0±
0.1, 11.1±
0.1, 14.4±
0.1, 15.1±
0.1, 15.7±
0.1, 16.4±
0.1, 16.8±
0.1, and 19.6±
0.1.
- values (CuKα
-
37. A pharmaceutical combination comprising a therapeutically effective amount of crystalline compound of form N-3, H-1 (1H2O), H-1 (1PhCO2H/1H2O), or N-1, and at least one or more antidiabetic agent(s) other than a DPP4 inhibitor for treating diabetes, an antidiabetic agent other than a DPP4 inhibitor for treating diabetes, wherein the crystalline compound of form N-3 has powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 5.2±
0.1, 7.9±
0.1, 10.8±
0.1, 11.5±
0.1, 13.0±
0.1, 14.6±
0.1, 15.6±
0.1, 15.9±
0.1, and 16.5±
0.1;
wherein the crystalline compound of form H-1 (1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 12.4±
0.1, 13.3±
0.1, 13.6±
0.1, 14.7±
0.1, 16.2±
0.1, 18.2±
0.1, 19.9±
0.1, 20.9±
0.1, 21.9±
0.1, and 22.4±
0.1;
wherein the crystalline compound of form H-1 (1PhCO2H/1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.6±
0.1, 8.3±
0.1, 15.3±
0.1, 16.1±
0.1, 16.9±
0.1, 17.5±
0.1, 17.8±
0.1, 18.6±
0.1, and 21.3±
0.1; and
wherein the crystalline compound of form N-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.5±
0.1, 7.0±
0.1, 11.1±
0.1, 14.4±
0.1, 15.1±
0.1, 15.7±
0.1, 16.4±
0.1, 16.8±
0.1, and 19.6±
0.1. - View Dependent Claims (38, 39, 40, 41, 42)
- values (CuKα
-
43. A pharmaceutical combination comprising a therapeutically effective amount of crystalline compound of form N-3, H-1 (1H2O), H-1 (1PhCO2H/1H2O), or N-1, and an anti-obesity agent, wherein the crystalline compound of form N-3 has powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 5.2±
0.1, 7.9±
0.1, 10.8±
0.1, 11.5±
0.1, 13.0±
0.1, 14.6±
0.1, 15.6±
0.1, 15.9±
0.1, and 16.5±
0.1;
wherein the crystalline compound of form H-1 (1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 12.4±
0.1, 13.3±
0.1, 13.6±
0.1, 14.7±
0.1, 16.2±
0.1, 18.2±
0.1, 19.9±
0.1, 20.9±
0.1, 21.9±
0.1, and 22.4±
0.1;
wherein the crystalline compound of form H-1 (1PhCO2H/1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.6±
0.1, 8.3±
0.1, 15.3±
0.1, 16.1±
0.1, 16.9±
0.1, 17.5±
0.1, 17.8±
0.1, 18.6±
0.1, and 21.3±
0.1; and
wherein the crystalline compound of form N-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.5±
0.1, 7.0±
0.1, 11.1±
0.1, 14.4±
0.1, 15.1±
0.1, 15.7±
0.1, 16.4±
0.1, 16.8±
0.1, and 19.6±
0.1. - View Dependent Claims (44)
- values (CuKα
-
45. A pharmaceutical combination comprising a therapeutically effective amount of crystalline compound of form N-3, H-1 (1H2O), H-1 (1PhCO2H/1H2O), or N-1, and a lipid-modulating agent, wherein the crystalline compound of form N-3 has powder x-ray diffraction peaks at 2θ
- values (CuKα
λ
−
1.5418 Å
) of 5.2±
0.1, 7.9±
0.1, 10.8±
0.1, 11.5±
0.1, 13.0±
0.1, 14.6±
0.1, 15.6±
0.1, 15.9±
0.1, and 16.5±
0.1;
wherein the crystalline compound of form H-1 (1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 12.4±
0.1, 13.3±
00.1, 13.6±
0.1, 14.7±
0.1, 16.2±
0.1, 18.2±
0.1, 19.9±
0.1, 20.9±
0.1, 21.9±
0.1, and 22.4±
0.1;
wherein the crystalline compound of form H-1 (1PhCO2H/1H2O) has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 6.6±
0.1, 8.3±
0.1, 15.3±
0.1, 16.1±
0.1, 16.9±
0.1, 17.5±
0.1, 17.8±
0.1, 18.6±
0.1, and 21.3±
0.1; and
wherein the crystalline compound of form N-1 has powder x-ray diffraction peaks at 2θ
values (CuKα
λ
−
1.5418 Å
) of 5.5±
0.1, 7.0±
0.1, 11.1±
0.1, 14.4±
0.1, 15.1±
0.1, 15.7±
0.1, 16.4±
0.1, 16.8±
0.1, and 19.6±
0.1. - View Dependent Claims (46)
- values (CuKα
Specification